BB Biotech’s Juno Therapeutics, Inc. JUNO Stock Holding History

BB Biotech’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,925,000	Closed	-$88M	–	31
2017 Q4	$88M	Sell	1,925,000 -130,000	-6%	-$6.48M	2.48%	14
2017 Q3	$92.2M	Sell	2,055,000 -130,000	-6%	-$4.43M	2.55%	14
2017 Q2	$65.3M	Hold	2,185,000	–	–	2%	17
2017 Q1	$48.5M	Buy	2,185,000 +315,000	+17%	+$6.76M	1.59%	17
2016 Q4	$35.3M	Buy	1,870,000 +465,000	+33%	+$11.4M	1.31%	18
2016 Q3	$42.2M	Buy	1,405,000 +100,000	+8%	+$3.11M	1.48%	19
2016 Q2	$50.2M	Hold	1,305,000	–	–	1.98%	16
2016 Q1	$49.7M	Hold	1,305,000	–	–	1.98%	15
2015 Q4	$57.4M	Hold	1,305,000	–	–	1.62%	17
2015 Q3	$53.1M	Buy	1,305,000 +855,000	+190%	+$37.5M	1.68%	16
2015 Q2	$24M	Buy	+450,000	New	+$23.9M	0.65%	25

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

BB Biotech's JUNO Position: Q1 2018 in Review

BB Biotech sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 1,925,000 shares — an estimated $88M sold.

BB Biotech first reported a position in JUNO in Q2 2015 and held it in 11 quarters. The position peaked at $92.2M in Q3 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

BB Biotech reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
BB Biotech sold 1,925,000 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $88M.
BB Biotech first reported a position in Juno Therapeutics, Inc. in Q2 2015 and held it in 11 quarters.
BB Biotech's Juno Therapeutics, Inc. position peaked at $92.2M in Q3 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on BB Biotech's 13F filing for Q1 2018, filed 8 May 2018.